The Corner

Health Care

Major Swedish Hospital Bans Puberty Blocking for Gender Dysphoria

(Sergey Tinyakov/Getty Images)

The actual science is beginning to overcome transgender ideology. First, the U.K.’s National Institute for Health and Care Excellence — basically the NHS’s decision-maker for what to cover — determined that there was “very low” evidence of benefit to allow children with gender dysphoria to have their natural puberty blocked — which is an “off label” use of those drugs, by the way.

Now, Karolinska Hospital, a major health institution in Sweden, is stopping their use. First, there is little scientific to support such interventions. From the hospital’s official statement:

In December 2019, the SBU (Swedish Agency for Health Technology Assessment and Assessment of Social Services) published an overview of the knowledge base which showed a lack of evidence for both the long-term consequences of the treatments, and the reasons for the large influx of patients in recent years.

Even more importantly, the potential for harming the patient physically is very real:

These treatments are potentially fraught with extensive and irreversible adverse consequences such as cardiovascular disease, osteoporosis, infertility, increased cancer risk, and thrombosis. This makes it challenging to assess the risk/benefit for the individual patient, and even more challenging for the minors and their guardians to be in a position of an informed stance regarding these treatments.

Yikes!

As a consequence the hospital wisely enacted the following policy:

In light of the above, and based on the precautionary principle, which should always be applied, it has been decided that hormonal treatments (i.e., puberty blocking and cross-sex hormones) will not be initiated in gender dysphoric patients under the age of 16.

For patients between ages 16 and 18, it has been decided that treatment may only occur within the clinical trial settings approved by the EPM (Ethical Review Agency/Swedish Institutional Review Board). The patient must receive comprehensive information about potential risks of the treatment, and a careful assessment of the patient’s maturity level must be conducted to determine if the patient is capable of evaluating, and consenting to, the treatment.

Maybe the American Academy of Pediatrics will also come to its senses and reconsider that organization’s misguided policy supporting puberty blocking. Alas, I am not holding my breath. Transgender ideology sparked an acute moral panic that — more than in-depth scientific research — led to allowing puberty blocking of gender-dysphoric children.

Now — will the usual woke major corporations organize a boycott of Sweden for being “transphobic?” Or is such bullying reserved exclusively for the U.S.?

Recommended

The Latest